Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
May's 5 Dividend Growth Stocks With 5.49%+ Yields
02:09pm, Friday, 17'th May 2024
Dividend growth stocks can provide reliable cash flows and help to build long-term wealth for income investors. Every month we look at screening dividend stocks based on safety, growth, and consistenc
Trade Tracker: Goldman Sachs, Bristol Myers and TJX
01:43pm, Friday, 17'th May 2024
The Investment Committee shares their latest portfolio moves.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #EADV--New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis.
Bristol Myers (BMY) Gets FDA Nod for Breyanzi Label Expansion
09:35am, Thursday, 16'th May 2024
Bristol Myers Squibb (BMY) obtains FDA approval for the label expansion of CAR T cell therapy Breyanzi to treat adult patients with relapsed or refractory follicular lymphoma.
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
07:15am, Thursday, 16'th May 2024
It's no secret that artificial intelligence ( AI ) promises to transform every industry and sector, pharma included. But how do those companies plan to leverage AI, and what will it do for their stoc
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
Bristol-Myers Squibb Company (BMY) Bank of America Global Healthcare Conference 2024 Transcript
07:58pm, Wednesday, 15'th May 2024
Bristol-Myers Squibb Company (NYSE:BMY ) Bank of America Global Healthcare Conference 2024 May 15, 2024 2:20 PM ET Company Participants David Elkins – Executive Vice President and Chief Financial Of
US FDA approves expanded use of Bristol's cancer cell therapy
05:01pm, Wednesday, 15'th May 2024
The U.S. Food and Drug Administration on Wednesday approved the expanded use of Bristol Myers Squibb's cancer cell therapy Breyanzi to include the treatment of adults with a type of blood cancer that
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
10:02am, Wednesday, 15'th May 2024
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Dividend Capture Captains: The 3 Best Blue-Chip Stocks for Tactical Traders
06:46am, Tuesday, 14'th May 2024
Give someone a dividend and you pay them that day but teach them to capture the dividend and you provide investment income for life! Executing a capture-the-dividend trade entails buying the stock b
Bristol-Myers Squibb dragged down the S&P 500 this earnings season
05:24pm, Monday, 13'th May 2024
More than 90% of the companies in the S&P 500 (^GSPC) have reported their earnings for the first quarter of 2024, which yielded a mostly strong result for the index. However, Bristol-Myers Squibb (BMY
Bristol-Myers Squibb Company (BMY) Presents at Guggenheim Securities Radiopharmaceuticals Day (Transcript)
02:23pm, Monday, 13'th May 2024
Bristol-Myers Squibb Company. (NYSE:BMY ) Guggenheim Securities Radiopharmaceuticals Day May 13, 2024 11:00 AM ET Company Participants Ben Hickey - President RayzeBio, Head of Mirati Conference Call P
Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study
12:21pm, Monday, 13'th May 2024
Bristol Myers' (BMY) late-stage label-expanding study evaluating the Opdivo/Yervoy combination fails to meet the primary endpoint of progression-free survival in unresectable stage III NSCLC.
Down but Not Out: 3 Stocks to Buy on a Post-Earnings Dip
04:45am, Sunday, 12'th May 2024
Starbucks is still seeing strong traffic, despite its earnings miss. Datadog's longer-term prospects look better than its short-term hiccup.
Is Bristol Myers' Dividend in Danger?
07:29am, Saturday, 11'th May 2024
Expenses related to acquisitions recently weighed down Bristol Myers' earnings results. The company, however, still generates strong free cash flow.
